{"disease":{"id":"vivax-malaria","name":"Vivax malaria","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":9,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"artesunate","indication_name":"Vivax malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Artesunate","generic_name":"ARTESUNATE","company_name":"Amivas","drug_phase":"marketed","molecular_target":"","drug_class":"artesunate","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"hydroxychloroquine-pill","indication_name":"Vivax malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hydroxychloroquine Sulfate","generic_name":"hydroxychloroquine-pill","company_name":"Sanofi","drug_phase":"discontinued","molecular_target":"Toll-like receptor 9","drug_class":"Antimalarial","quality_score":null,"revenue":null,"mechanism":"Hydroxychloroquine Sulfate works by interfering with the replication of malaria parasites and modulating the immune system to treat autoimmune diseases."},{"drug_id":"halofantrine","indication_name":"Vivax malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Halfan","generic_name":"HALOFANTRINE","company_name":"GSK","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Antimalarial","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"arsuamoon","indication_name":"Vivax malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Arsuamoon","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":7,"revenue":null,"mechanism":null},{"drug_id":"mefloquine","indication_name":"Vivax malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lariam","generic_name":"MEFLOQUINE","company_name":"","drug_phase":"marketed","molecular_target":"Adenosine receptor A2a","drug_class":"Antimalarial","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"chloroquine","indication_name":"Vivax malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aralen","generic_name":"CHLOROQUINE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Sigma non-opioid intracellular receptor 1","drug_class":"Antimalarial","quality_score":65,"revenue":null,"mechanism":"Aralen works by accumulating in the acidic compartments of the malaria parasite, disrupting its metabolism and ultimately leading to its death."},{"drug_id":"hydroxychloroquine","indication_name":"Vivax malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hydroxychloroquine Sulfate","generic_name":"HYDROXYCHLOROQUINE","company_name":"Advanz","drug_phase":"marketed","molecular_target":"Toll-like receptor 9","drug_class":"Antimalarial","quality_score":75,"revenue":null,"mechanism":"Hydroxychloroquine Sulfate works by interfering with the replication of malaria parasites and reducing inflammation in the body."},{"drug_id":"mefloquine-hydrochloride","indication_name":"Vivax malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lariam","generic_name":"MEFLOQUINE HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"Adenosine receptor A2a","drug_class":"Antimalarial","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"hydroxychloroquin","indication_name":"Vivax malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxychloroquin","company_name":"Children's Hospital of Fudan University","drug_phase":"marketed","molecular_target":"Transmembrane protein 97, Alpha-1D adrenergic receptor, Alpha-2A adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":9,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05052502","title":"Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand","phase":"NA","overall_status":"UNKNOWN","enrollment_count":49118,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT04416945","title":"Targeting High Risk Populations With Enhanced Reactive Case Detection in Southern Lao Peoples Democratic Republic","phase":"NA","overall_status":"UNKNOWN","enrollment_count":31443,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT06923592","title":"Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":19200,"lead_sponsor_name":"London School of Hygiene and Tropical Medicine","has_results":false},{"nct_id":"NCT05690841","title":"FocaL Mass Drug Administration for Vivax Malaria Elimination","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":7530,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT05879224","title":"Short Course Primaquine for the Radical Cure of P. Vivax Malaria - Indonesia","phase":"NA","overall_status":"COMPLETED","enrollment_count":2999,"lead_sponsor_name":"Menzies School of Health Research","has_results":false},{"nct_id":"NCT06575647","title":"Vivax Elimination With Tafenoquine (VET) Study","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1242,"lead_sponsor_name":"Shoklo Malaria Research Unit","has_results":false},{"nct_id":"NCT06148792","title":"A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1090,"lead_sponsor_name":"Menzies School of Health Research","has_results":false},{"nct_id":"NCT04411836","title":"Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":960,"lead_sponsor_name":"Menzies School of Health Research","has_results":false},{"nct_id":"NCT05058885","title":"Plasmodium Vivax Among Duffy Negative Population in Cameroon.","phase":"","overall_status":"UNKNOWN","enrollment_count":900,"lead_sponsor_name":"University of Dschang","has_results":false},{"nct_id":"NCT05874271","title":"Short Course Primaquine for the Radical Cure of P. Vivax - Papua New Guinea","phase":"NA","overall_status":"COMPLETED","enrollment_count":794,"lead_sponsor_name":"Macfarlane Burnet Institute for Medical Research and Public Health Ltd","has_results":false},{"nct_id":"NCT02001428","title":"Malaria in Early Life Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":757,"lead_sponsor_name":"Gadjah Mada University","has_results":false},{"nct_id":"NCT04704999","title":"Southeast Asia Dose Optimization of Tafenoquine","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT05788094","title":"ACT vs CQ With Tafenoquine for P. Vivax Mono-infection","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":606,"lead_sponsor_name":"Shoklo Malaria Research Unit","has_results":false},{"nct_id":"NCT03916003","title":"Reducing the Risk of P. Vivax After Falciparum Infections in Co-endemic Areas","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Menzies School of Health Research","has_results":false},{"nct_id":"NCT00138489","title":"Papua New Guinean Duffy Negativity And Vivax Malar","phase":"","overall_status":"TERMINATED","enrollment_count":266,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT03610399","title":"Efficacy of 3 Regimens of Chloroquine and Primaquine for Treatment of P. Vivax Malaria, Cruzeiro do Sul, Acre, Brazil","phase":"NA","overall_status":"COMPLETED","enrollment_count":257,"lead_sponsor_name":"Centers for Disease Control and Prevention","has_results":true},{"nct_id":"NCT04706130","title":"Rigorous Assessment of P. Vivax Relapses and Primaquine Efficacy for Radical Cure","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":160,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":false},{"nct_id":"NCT04222088","title":"TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014","phase":"","overall_status":"COMPLETED","enrollment_count":159,"lead_sponsor_name":"Research Institute for Tropical Medicine, Philippines","has_results":true},{"nct_id":"NCT03529396","title":"Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in G6PD Deficient Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":106,"lead_sponsor_name":"Fundação de Medicina Tropical Dr. Heitor Vieira Dourado","has_results":false},{"nct_id":"NCT04228315","title":"Biomarkers of P. Vivax Relapse","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Armed Forces Research Institute of Medical Sciences, Thailand","has_results":false},{"nct_id":"NCT07468513","title":"Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases.","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Menzies School of Health Research","has_results":false},{"nct_id":"NCT06044805","title":"Therapeutic Efficacy of Chloroquine Plus Primaquine in the Treatment of Uncomplicated Plasmodium Vivax","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Dinka Dugassa","has_results":false},{"nct_id":"NCT05958797","title":"TES of Chloroquine for Pv in the Philippines in 2016","phase":"","overall_status":"COMPLETED","enrollment_count":74,"lead_sponsor_name":"Research Institute for Tropical Medicine, Philippines","has_results":false},{"nct_id":"NCT07373301","title":"Phase IIa/b Trial of PvCS/Montanide ISA-51 Malaria Vaccine in Adults in Chocó, Colombia","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":72,"lead_sponsor_name":"Malaria Vaccine and Drug Development Center","has_results":false},{"nct_id":"NCT06036030","title":"Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West Papua","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Syamsudin Abdillah,Ph.D, Pharm D","has_results":false},{"nct_id":"NCT05380388","title":"A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 )","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":36,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT04079621","title":"Short Course Radical Cure of P. Vivax Malaria in Nepal","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Menzies School of Health Research","has_results":false},{"nct_id":"NCT00295581","title":"PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":0,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false}],"total":28},"guidelines":[],"source":"Drug Landscape verified database"}